Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 May;102(5):1112; author reply 1113.
doi: 10.1111/j.1349-7006.2011.01905.x.

Japanese patients equally likely to benefit from aprepitant for chemotherapy-induced nausea and vomiting prevention

João Paulo da Silveira Nogueira Lima, Ricardo Akiyoshi Nakamura, Lucas Vieira dos Santos
Comment

Japanese patients equally likely to benefit from aprepitant for chemotherapy-induced nausea and vomiting prevention

João Paulo da Silveira Nogueira Lima et al. Cancer Sci. 2011 May.

Abstract

(Cancer Sci 2011; 102: 1113)

PubMed Disclaimer

Comment on

References

    1. Lima JP, Nakamura RA, dos Santos LV. Japanese patients equally likely to benefit from aprepitant for chemotherapy‐induced nausea and vomiting prevention. Cancer Sci 2011; 102: 1112. - PubMed
    1. Takahashi T, Hoshi E, Takagi M et al. Multicenter, phase II, placebo‐controlled, double‐blind, randomized study of aprepitant in Japanese patients receiving high‐dose cisplatin. Cancer Sci 2010; 101: 2455–61. - PMC - PubMed
    1. Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting. Cancer 2003; 97 (9): 2290–300. - PubMed
    1. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin‐1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting: a multinational, randomized, double‐blind, placebo‐controlled trial in patients receiving high‐dose cisplatin‐‐the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21 (22): 4112–9. Epub 2003 October 14. - PubMed
    1. Poli‐Bigelli S, Rodrigues‐Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting. Results from a randomized, double‐blind, placebo‐controlled trial in Latin America. Cancer 2003; 97 (12): 3090–8. - PubMed

MeSH terms